Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening

Journal of Molecular Neuroscience

Volumn 20, Issue 3, 2003, Pages 305-313

  Chang, Lei ^a   Bakhos, Lara ^a   Wang, Zhiqiang ^b   Venton, Duane L ^b   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ADDLs; Alzheimer's disease; Amyloid ; Cyclodextrin; Drug screening; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN DERIVED DIFFUSIBLE LIGAND; AMYLOID PRECURSOR PROTEIN; CYCLODEXTRIN DERIVATIVE; LIGAND; OLIGOMER; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT; POLYMER;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; IMMUNOASSAY; IMMUNODETECTION; MOUSE; NEUROTOXICITY; NONHUMAN; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BRAIN; CELL STRAIN; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOBLOTTING; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALIA; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BETA-CYCLODEXTRINS; BLOTTING, WESTERN; BRAIN; CYCLODEXTRINS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; IMMUNOBLOTTING; MICE; MICE, TRANSGENIC; PC12 CELLS; PEPTIDE FRAGMENTS; POLYMERS; PREDICTIVE VALUE OF TESTS; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0242479694     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:3:305     Document Type: Article

References (29)

1. Bohrmann B., Adrian M., Dubochet J., Kuner P., Muller F., Huber W., et al. (2000) Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130, 232-246.
2. D'Hooge R., Nagels G., Westland C. E., Mucke L., and De Deyn P. P. (1996) Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. Neuroreport 7, 2807-2811.
3. Dodart J. C., Bales K. R., Gannon K. S., Greene S. J., DeMattos R. B., Mathis C., et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat.Neurosci. 5, 452-457.
4. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
5. Harper J. D. and Lansbury P. T., Jr. (1997) Models of amyloid seeding in Alzheimer 's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407.
6. Harper J. D., Wong S. S., Lieber C. M., and Lansbury P. T., Jr. (1999) Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer 's disease. Biochemistry 38, 8972-8980.
7. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884.
8. Holcomb L., Gordon M. N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100.
9. Hsia A. Y., Masliah E., McConlogue L., Yu G. Q., Tatsuno G., Hu K., et al. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228-3233.
10. Klein W. L., Krafft G. A., and Finch C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224.
11. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., et al. (1998) Diffusible, nonfibrillar ligands derived from A beta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
12. Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E., Yu J., et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595-605.
13. Lorenzo A. and Yankner B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12,243-12,247.
14. McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
15. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492.
16. Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., et al. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058.
17. Nybo M., Svehag S. E., and Holm N. E. (1999) An ultrastructural study of amyloid intermediates in A beta1-42 fibrillogenesis. Scand. J. Immunol. 49, 219-223.
18. Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., et al. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37, 3602-3611.
19. Potempska A., Mack K., Mehta P., Kim K. S., and Miller D. L. (1999) Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides. Amyloid 6, 14-21.
20. Sian A. K., Frears E. R., El Agnaf O. M., Patel B. P., Manca M. F., Siligardi G., et al. (2000) Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem. J. 349, 299-308.
21. Small G. W., Rabins P. V., Barry P. P., Buckholtz N. S., DeKosky S. T., Ferris S. H., et al. (1997) Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278, 1363-1371.
22. Southwick P. C., Yamagata S. K., Echols C. L., Jr., Higson G. J., Neynaber S. A., Parson R. E., et al. (1996) Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J. Neurochem. 66, 259-265.
23. Terry R. D., ed. (1999) The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations, in Alzheimer Disease, Terry, Lippincott Williams & Wilkins, Philadelphia, PA, pp. 187-206.
24. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
25. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., and Teplow D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22,364-22,372.
26. Wang H. W., Pasternak J. F., Kuo H., Ristic H., Lambert M. P., Chromy B., et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140.
27. Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., et al. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867.
28. Wolfe M. S. (2002) Secretase as a target for Alzheimer's disease. Curr. Top. Med. Chem. 2, 371-383.
29. Yu J., Bakhos L., Chang L., Holterman M. J., Klein W. L., and Venton D. L. (2002) Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J. Mol. Neurosci. 19, 51-55.